Treatment sequences and drug costs from diagnosis to death in multiple myeloma.

Autor: Seefat, M. R., Cucchi, D. G. J., Groen, K., Donker, M. L., van der Hem, K. G., Westerman, M., Gerrits, A. M., Beeker, A., van de Donk, N. W. C. J., Blommestein, H. M., Zweegman, S.

Publikováno v: European Journal of Haematology; Mar2024, Vol. 112 Issue 3, p360-366, 7p

Carfilzomib for relapsed and refractory multiple myeloma

Autor: Groen K, van de Donk NWCJ, Stege CAM, Zweegman S, Nijhof IS

Publikováno v: Cancer Management and Research, Vol Volume 11, Pp 2663-2675 (2019)

K Groen, NWCJ van de Donk, CAM Stege, S Zweegman, IS Nijhof Department of Hematology, VU University Medical Center, Amsterdam, Netherlands Abstract: Although the prognosis of multiple myeloma (MM) patients has dramatically improved during recent year

Externí odkaz: https://doaj.org/article/90fe6e5765eb4678aa10dcf4ac8bad8d

Antibody Response in Immunocompromised Patients with Hematologic Cancers Who Received a 3-Dose mRNA-1273 Vaccination Schedule for COVID-19

Autor: Haggenburg, S., Hofsink, Q., Lissenberg-Witte, B.I., Broers, A.E.C., Doesum, J.A. van, Binnendijk, R.S. van, Hartog, G. den, Bhoekhan, M.S., Haverkate, N.J.E., Burger, J.A., Bouhuijs, J.H., Smits, G.P., Wouters, D., Leeuwen, E.M.M. van, Bontkes, H.J., Kootstra, N.A., Zweegman, S., Kater, A.P., Heemskerk, M.H.M., Groen, K., Meerten, T. van, Mutsaers, P.G.N.J., Beaumont, T., Gils, M.J. van, Goorhuis, A., Rutten, C.E., Hazenberg, M.D., Nijhof, I.S., Cobra Kai Study Team

Publikováno v: Haggenburg, S, Hofsink, Q, Lissenberg-Witte, B I, Broers, A E C, van Doesum, J A, van Binnendijk, R S, den Hartog, G, Bhoekhan, M S, Haverkate, N J E, Burger, J A, Bouhuijs, J H, Smits, G P, Wouters, D, van Leeuwen, E M M, Bontkes, H J, Kootstra, N A, Zweegman, S, Kater, A P, Heemskerk, M H M, Groen, K, van Meerten, T, Mutsaers, P G N J, Beaumont, T, van Gils, M J, Goorhuis, A, Rutten, C E, Hazenberg, M D & Nijhof, I S 2022, ' Antibody Response in Immunocompromised Patients with Hematologic Cancers Who Received a 3-Dose mRNA-1273 Vaccination Schedule for COVID-19 ', JAMA Oncology, vol. 8, no. 10, pp. 1477-1483 . https://doi.org/10.1001/jamaoncol.2022.3227
JAMA Oncology, 8(10), 1477-1483. American Medical Association
JAMA oncology, 8(10), 1477-1483. AMER MEDICAL ASSOC
JAMA Oncology, 8(10), 1477-1483. AMER MEDICAL ASSOC
JAMA oncology, 8(10), 1477-1483. American Medical Association

ImportanceIt has become common practice to offer immunocompromised patients with hematologic cancers a third COVID-19 vaccination dose, but data substantiating this are scarce.ObjectiveTo assess whether a third mRNA-1273 vaccination is associated wit

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4540836a714070839e1bdeed6825e303
https://research.vumc.nl/en/publications/7c4334ec-660d-4280-8ec8-447119d024c7

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.